Efficacy and Safety of L Arginine to Prevent Preeclampsia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02363348|
Recruitment Status : Completed
First Posted : February 16, 2015
Last Update Posted : March 4, 2016
Randomized double-blind controled clinical trial to assess the efficacy and safety of L-arginine to prevent preeclampsia.
applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes
|Condition or disease||Intervention/treatment||Phase|
|Preeclampsia||Dietary Supplement: L arginine Other: Placebo||Phase 3|
Two groups were formed. one received L arginine 3 grams orally at day from the 20th week of pregnancy. the other group received placebo.
Each three weeks were evaluated in search of high blood pressure and proteinuria.
The follow-up was until the end of pregnancy and two weeks after this
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Efficacy and Safety of L Arginine to Prevent Preeclampsia in High Risk Pregnancies|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||March 2014|
Placebo Comparator: Placebo (A)
were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.
dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Experimental: L arginine (B)
were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Dietary Supplement: L arginine
L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
- efficacy of L arginine to prevent preeclampsia [ Time Frame: from time of randomization until the date of diagnostic of preeclampsia or two weeks after delivery wichever came first. approximalety 20 weeks. ]number of patients with diagnosis of preeclampsia. the diagnostic was performed when they presented arterial blood pressure above 140/90 mm / Hg in the span of 6 hours and accompanied by proteinuria (>300 milligrams in one sample) number of patients with high blood pression and proteinuria (ACOG criteria) The evaluations were performed every three weeks until week 31, then every two weeks until week 35 and weekly until pregnancy ended
- perinatal outcome [ Time Frame: from time to delivery until two weeks after, approximalety 18 weeks ]number of patients with adverse perinatal outcome: APGAR scale < 7 at five minutes, low weight for gestational age (< 10 percentile) and CAPURRO scale < 37 weeks also the need to enter the neonatal intensive care unit
- safety of L arginine [ Time Frame: from time of randomization until birth approximalety 18 weeks ]number of patients with adverse reactions and/or any alteration of blood test. participants are awarded a diary which recorded the symptoms that caused them any discomfort. If the discomfort was important it was reported via telephone with the treating physician. the paper was reviewed at each appointment. Blood tests such as blood count, liver function tests and kidney were performed every three weeks in search of alterations in the parameters considered normal by those tests (ACOG criteria)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363348
|Panduro Baron J Guadalupe|
|Guadalajara, Jalisco, Mexico, 44340|
|Study Chair:||Guadalupe Panduro, Ph||Hospital Civil Juan I. Menchaca|